Loading...
•
Jun 30
Organogenesis Q2 2025 Earnings Report
Organogenesis Holdings Inc. reported its financial results for the second quarter ended June 30, 2025, showing a decrease in net product revenue and a net loss, though the net loss was reduced compared to the prior year.
Key Takeaways
Organogenesis Holdings Inc. reported a net product revenue of $100.8 million for the second quarter of 2025, a 23% decrease year-over-year. The company experienced a net loss of $9.4 million, which was an improvement from the $17.0 million net loss in the same period last year. Advanced Wound Care product revenue decreased significantly, while Surgical & Sports Medicine products saw an increase.
Net product revenue for Q2 2025 was $100.8 million, a 23% decrease from $130.2 million in Q2 2024.
The company reported a net loss of $9.4 million in Q2 2025, an improvement from a $17.0 million net loss in Q2 2024.
Advanced Wound Care product revenue decreased by 25% to $92.7 million, while Surgical & Sports Medicine product revenue increased by 16% to $8.1 million.
Adjusted EBITDA was a loss of $3.6 million in Q2 2025, compared to an income of $15.6 million in Q2 2024.
Organogenesis
Organogenesis
Organogenesis Revenue by Segment
Revenue by Segment
Advanced Wound Care Revenue
CapyFin.comSurgical & Sports Medicine Revenue
CapyFin.com Forward Guidance
For the full fiscal year 2025, Organogenesis expects net product revenue between $480.0 million and $510.0 million, representing a range from roughly flat to a 6% increase year-over-year. The company also provided guidance for net income (loss) and adjusted net income, as well as EBITDA and Adjusted EBITDA.
Positive Outlook
- Expected net product revenue for 2025 is between $480.0 million and $510.0 million, potentially increasing up to 6% year-over-year.
- Surgical & Sports Medicine products are projected to increase revenue by 6% to 23% year-over-year.
- Anticipated net income (loss) for 2025 is between -$6.4 million and $16.4 million.
- Adjusted net income is projected to be between $5.5 million and $28.3 million for 2025.
- Adjusted EBITDA is expected to be between $31.1 million and $61.9 million for 2025.
Challenges Ahead
- Advanced Wound Care products are projected to have a revenue change ranging from a 1% decrease to a 5% increase year-over-year.
- The company acknowledges the impact and uncertainty of potential changes to coverage and reimbursement levels for its products, including proposed LCDs and CMS rules taking effect in 2026.
- Significant and continuing competition could adversely affect the business.
- Rapid technological change could make the company's products obsolete if product offerings are not enhanced.
- The company's ability to maintain production or obtain sufficient supply of products to meet demand is a risk factor.
Revenue & Expenses
Visualization of income flow from segment revenue to net income